Jimi Stewart, a rollerblading enthusiast from Austin, Texas, was diagnosed with a type of non-muscle invasive bladder cancer ...

Leerink Partners analysts slashed their sales forecast for enGene Therapeutics’ bladder cancer candidate after phase 2 data ...

Preliminary findings were presented at the 2025 ASCO Genitourinary Cancers Symposium. 2 Investigators reported that 71% of ...

A large real-world study examines outcomes and treatment patterns among patients with non-muscle-invasive bladder cancer treated with BCG.

Itay: Researchers have found in a new study that a single postoperative dose of Mitomycin C significantly reduces early ...

( NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced it will present new treatment comparison results evaluating ANKTIVA ® (nogapendekin alfa inbakicept-pmln) plus Bacillus ...

Trial shows promise: enGene’s gene therapy for high-risk, BCG-unresponsive bladder cancer achieved a 54% complete response rate, with low progression to advanced disease. Device gains clearance: ...

Gene (NASDAQ:ENGN) reported preliminary data from the pivotal Cohort 1 of its ongoing Phase 2 LEGEND trial evaluating detalimogene voroplasmide, or detalimogene, in patients with high-risk ...

Bladder-intact disease-free survival was 60% 2 years posttreatment with pembrolizumab combined with gemcitabine-based chemoradiation.

NMIBC treatment varies by tumor stage, grade, and prior therapies, with high-risk cases often requiring radical cystectomy. Bladder-preserving approaches include intravesical therapies like BCG, ...

Most people with bladder cancer begin treatment by having surgery to remove their cancer. If bladder cancer has spread beyond your bladder, you might have chemotherapy first. This can help treat ...